» Authors » G Parruti

G Parruti

Explore the profile of G Parruti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 49
Citations 305
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Santarone S, Natale A, Olioso P, Onofrillo D, DIncecco C, Parruti G, et al.
Bone Marrow Transplant . 2016 Nov; 52(3):388-393. PMID: 27819690
The aim of this study was to investigate the methods of conception and delivery, as well as the course and outcome of 42 pregnancies occurring in 15 female patients (27...
2.
Di Maio V, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, et al.
J Antimicrob Chemother . 2015 Dec; 71(3):739-50. PMID: 26679249
Objectives: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. Methods:...
3.
Pollicita M, Alteri C, Bellocchi M, Armenia D, Carioti L, Salpini R, et al.
Clin Microbiol Infect . 2015 Aug; 21(12):1124.e1-4. PMID: 26260987
In this study, by phylogenetic analysis, we identified an epidemiological cluster involving eight individuals diagnosed with acute hepatitis B virus (HBV) infection related to unprotected sexual intercourse in a restricted...
4.
Menzaghi B, Ricci E, Vichi F, De Sociod G, Carenzi L, Martinelli C, et al.
Biomed Pharmacother . 2014 Mar; 68(3):385-90. PMID: 24613008
Objectives: Evaluate gender differences with regard to baseline characteristics and outcome of therapy in cohorts of the SCOLTA (surveillance cohort long-term toxicity of antiretrovirals) project. Methods: The SCOLTA project is...
5.
Svicher V, Alteri C, Montano M, Nori A, DArrigo R, Andreoni M, et al.
Infection . 2013 Oct; 42(1):61-71. PMID: 24146352
Purpose: We have developed a sequencing assay for determining the usage of the genotypic HIV-1 co-receptor using peripheral blood mononuclear cell (PBMC) DNA in virologically suppressed HIV-1 infected patients. Our...
6.
Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, et al.
J Med Virol . 2013 Apr; 85(6):996-1004. PMID: 23588725
While the selection of complex HBV drug-resistance patterns on therapeutic failure can compromise the efficacy of anti-HBV therapies, recent data show that patients failing treatment without drug-resistance have a rate...
7.
Bucciardini R, DEttorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer L, et al.
Int J STD AIDS . 2012 Jul; 23(7):459-63. PMID: 22843997
We evaluated rates and determinants of virological failure in triple-class experienced patients receiving raltegravir-based regimens from a national observational study over 48 weeks, defined by any one of the following:...
8.
Colafigli M, Torti C, Trecarichi E, Albini L, Rosi A, Micheli V, et al.
Clin Microbiol Infect . 2012 Apr; 18(8):E299-304. PMID: 22536753
Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a...
9.
Ursini T, Polilli E, Congedo G, Tontodonati M, Di Masi F, Mazzotta E, et al.
Case Rep Dermatol . 2011 Nov; 3(2):175-80. PMID: 22059074
Giant warts are infrequent dermatological viral infections caused by Papillomavirus (HPV) in immune-compromised patients. Treatment may often be difficult and unsatisfactory, either by surgery or cytotoxic agents, because of poor...
10.
Polilli E, Parruti G, Fazii P, DAntonio D, Palmieri D, DIncecco C, et al.
Euro Surveill . 2011 Jun; 16(24). PMID: 21699768
In April 2011, an outbreak of Serratia marcescens infection/ colonisations occurred in the neonatal intensive care unit of Pescara General Hospital. Rapid microbiological investigations lead to identification of five cases...